The effects of BMS-470539 on lipopolysaccharideinduced acute lung injury
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Overactivation of inflammatory cells, including macrophages and neutrophils, is associated with acute lung injury. BMS-470539 is a selective agonist of melanocortin 1 receptor, which triggers the inhibition of proinflammatory responses, suppressing neutrophil infiltration and protecting tissue. This study evaluated the effects of BMS-470539 on lipopolysaccharide-induced acute lung injury in a mouse model. Methods: Mice received a subcutaneous injection of saline or BMS-470539 (18.47 mg/kg) 1 hour before an intratracheal injection of saline or lipopolysaccharide (20 μg). Mice were sacrificed to analyze the severity of pulmonary edema (lung wet-to-dry weight [W/D] ratio) and inflammatory responses (level of leukocytes, polymorphonuclear neutrophils [PMNs] and tumor necrosis factor alpha [TNF-α] in bronchoalveolar lavage fluid [BALF]), and neutrophil infiltration (myeloperoxidase activity). TNF-α activation was also measured in neutrophils from bone marrow. Survival was investigated in a second-hit sepsis mouse model. Results: BMS-470539 improved sepsis-induced pulmonary edema, as demonstrated by a decreased W/D ratio (5.76% ± 0.83% to 3.81% ± 0.86%, P < 0.05). The inflammatory response also improved, as shown by decreased levels of leukocytes (551 ± 116 to 357 ± 86 × 10²/mm³, P < 0.05), PMNs (51.52% ± 16.23% to 18.41% ± 7.25%, P < 0.01), and TNF-α (550 ± 338 to 128 ± 52 pg/ml, P < 0.01) in the BALF. BMS-470539 also improved the inflammatory response, as shown by TNF-α levels (850 ± 158 to 423 ± 59 pg/ml, P < 0.01) in neutrophils. BMS-470539 downregulated neutrophil infiltration in the lung (myeloperoxidase: 654 ± 98 to 218 ± 89 U/g, P < 0.001). Lastly, BMS improved the survival rate (0% to 70%, P < 0.01) in a mice multiple organ failure model. Conclusions: BMS-470539 improved lipopolysaccharide-induced acute lung injury and mortality in mice by affecting the inflammatory response.
Abstract
Background: Overactivation of inflammatory cells, including macrophages and neutrophils, is associated with acute lung injury. BMS-470539 is a selective agonist of melanocortin 1 receptor, which triggers the inhibition of proinflammatory responses, suppressing neutrophil infiltration and protecting tissue. This study evaluated the effects of BMS-470539 on lipopolysaccharide-induced acute lung injury in a mouse model. Methods: Mice received a subcutaneous injection of saline or BMS-470539 (18.47 mg/kg) 1 hour before an intratracheal injection of saline or lipopolysaccharide (20 μg). Mice were sacrificed to analyze the severity of pulmonary edema (lung wet-to-dry weight [W/D] ratio) and inflammatory responses (level of leukocytes, polymorphonuclear neutrophils [PMNs] and tumor necrosis factor alpha [TNF-α] in bronchoalveolar lavage fluid [BALF]), and neutrophil infiltration (myeloperoxidase activity). TNF-α activation was also measured in neutrophils from bone marrow. Survival was investigated in a second-hit sepsis mouse model. Results: BMS-470539 improved sepsis-induced pulmonary edema, as demonstrated by a decreased W/D ratio (5.76% ± 0.83% to 3.81% ± 0.86%, P < 0.05). The inflammatory response also improved, as shown by decreased levels of leukocytes (551 ± 116 to 357 ± 86 × 10²/mm³, P < 0.05), PMNs (51.52% ± 16.23% to 18.41% ± 7.25%, P < 0.01), and TNF-α (550 ± 338 to 128 ± 52 pg/ml, P < 0.01) in the BALF. BMS-470539 also improved the inflammatory response, as shown by TNF-α levels (850 ± 158 to 423 ± 59 pg/ml, P < 0.01) in neutrophils. BMS-470539 downregulated neutrophil infiltration in the lung (myeloperoxidase: 654 ± 98 to 218 ± 89 U/g, P < 0.001). Lastly, BMS improved the survival rate (0% to 70%, P < 0.01) in a mice multiple organ failure model. Conclusions: BMS-470539 improved lipopolysaccharide-induced acute lung injury and mortality in mice by affecting the inflammatory response.
참고문헌 (24)
- Wheeler AP, "Acute lung injury and the acute respiratory distress syndrome : a clinical review", Lancet, 369, pp.1553~1564 (2007)
- Bellani G, "Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries", JAMA, 315, pp.788~800 (2016)
- Dushianthan A, "Acute respiratory distress syndrome and acute lung injury", Postgrad Med J, 87, pp.612~622 (2011)
- Grommes J, "Contribution of neutrophils to acute lung injury", Mol Med, 17, pp.293~307 (2011)
- Chopra M, "apoptosis and signaling mechanisms", Exp Biol Med(Maywood), 234, pp.361~371 (2009)
- Wikberg JE, "New aspects on the melanocortins and their receptors", Pharmacol Res, 42, pp.393~420 (2000)
- Kang L, "A selective small molecule agonist of the melanocortin-1 receptor inhibits lipopolysaccharide-induced cytokine accumulation and leukocyte infiltration in mice", J Leukoc Biol, 80, pp.897~904 (2006)
- Gantz I, "The melanocortin system", Am J Physiol Endocrinol Metab, 284, pp.E468~74 (2003)
- Maaser C, "Crucial role of the melanocortin receptor MC1R in experimental colitis", Gut, 55, pp.1415~1422 (2006)
- Leoni G, "The melanocortin MC(1)receptor agonist BMS-470539inhibits leucocyte trafficking in the inflamed vasculature", Br J Pharmacol, 160, pp.171~180 (2010)
- Chen W, "The melanocortin 1 receptor (MC1R) inhibits the inflammatory response in Raw 264.7 cells and atopic dermatitis (AD) mouse model", Mol Biol Rep, 40, pp.1987~1996 (2013)
- Holloway PM, "Both MC1 and MC3 receptors provide protection from cerebral ischemia-reperfusion-induced neutrophil recruitment", Arterioscler Thromb Vasc Biol, 35, pp.1936~1944 (2015)
- Mykicki N, "Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease", Sci Transl Med, 8, pp.362~ (2016)[DOI]
- Qiang X, "New melanocortin-like peptide of E. coli can suppress inflammation via the mammalian melanocortin-1 receptor (MC1R): possible endocrine-like function for microbes of the gut", NPJ Biofilms Microbiomes, 3, pp.31~ (2017)
- Ito Y, "Lipopolysaccharide-induced neutrophilic inflammation in the lungs differs with age", Exp Lung Res, 33, pp.375~384 (2007)
- Kitamura Y, "Fas", FasL-dependent apoptosis of alveolar cells after lipopolysaccharide-induced lung injury in mice, 2001, pp.163, 762~769
- Ignar DM, "Regulation of TNF-alpha secretion by a specific melanocortin-1 receptor peptide agonist", Peptides, 24, pp.709~716 (2003)
- Montero-Melendez T, "Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects", J Immunol, 194, pp.3381~3388 (2015)
- Szarka RJ, "A murine model of pulmonary damage induced by lipopolysaccharide via intranasal instillation", J Immunol Methods, 202, pp.49~57 (1997)
- Patel BV, "TNF-induced death signaling triggers alveolar epithelial dysfunction in acute lung injury", J Immunol, 190, pp.4274~4282 (2013)
- Star RA, "Evidence of autocrine modulation of macrophage nitric oxide synthase by alpha-melanocyte-stimulating hormone", Proc Natl Acad Sci U S A, 92, pp.8016~8020 (1995)
- Catania A, "The neuropeptide alpha-MSH has specific receptors on neutrophils and reduces chemotaxis in vitro", Peptides, 17, pp.675~679 (1996)
- Gonindard C, "The administration of an alpha-MSH analogue reduces the serum release of IL-1 alpha and TNF alpha induced by the injection of a sublethal dose of lipopolysaccharides in the BALB", c mouse, 1996, pp.9, 148~153
- Bhardwaj RS, "Pro-opiomelanocortin-derived peptides induce IL-10 production in human monocytes", J Immunol, 156, pp.2517~2521 (1996)